Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

Milos Dokmanovic Division of Monoclonal Antibodies; Office of Biotechnology Products; Office of Pharmaceutical Science; Center for Drug Evaluation and Research; US Food and Drug Administration; Bethesda, MD USA

Yun Wu Department of Pathology; University of Texas M.D. Anderson Cancer Center; Houston, TX USA

Yi Shen Division of Monoclonal Antibodies; Office of Biotechnology Products; Office of Pharmaceutical Science; Center for Drug Evaluation and Research; US Food and Drug Administration; Bethesda, MD USA

Jieqing Chen Department of Pathology; University of Texas M.D. Anderson Cancer Center; Houston, TX USA

Dianne S Hirsch Division of Monoclonal Antibodies; Office of Biotechnology Products; Office of Pharmaceutical Science; Center for Drug Evaluation and Research; US Food and Drug Administration; Bethesda, MD USA

Wen Jin Wu Division of Monoclonal Antibodies; Office of Biotechnology Products; Office of Pharmaceutical Science; Center for Drug Evaluation and Research; US Food and Drug Administration; Bethesda, MD USACorrespondence[email protected]

Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

Additional material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

Additional material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date